Tirzepatide (Mounjaro) plateau management explained with FDA-label titration schedules, SURPASS trial data, real-world evidence, and a clinical decision framework for when and how to escalate dose.
Learn how to safely re-titrate Prometrium (micronized progesterone) after stopping, including starting doses, escalation schedules, what evidence says, and when to contact your provider.
Evidence-based muscle preservation strategies for patients using topical minoxidil 5% for androgenetic alopecia, with primary-literature citations and clinical protocols.
How seasons affect topical minoxidil 5% absorption, shedding cycles, and adherence. Evidence-based guidance on adjusting your regimen by season for androgenetic alopecia.
A clinical review of trazodone's effects on bone mineral density, fracture risk, and fall risk, covering mechanisms, trial data, and prescribing guidance for patients on long-term trazodone therapy.
A guide to trazodone missed-dose management, mechanism of action, pharmacokinetics, and evidence-based prescribing for depression and off-label insomnia.
A clinician-level guide to switching trazodone to or from other antidepressants, sleep agents, and related drugs. Covers mechanism, cross-tapering schedules, washout periods, and serotonin syndrome risk with specific doses and trial data.
How to time trazodone doses during transmeridian travel, manage jet lag, and adjust schedules across time zones. MD/PharmD-level protocols with primary-literature citations.
Evidence-based tretinoin dosing for adults aged 30-49, covering concentrations, application schedules, titration protocols, and management of common side effects for acne and photoaging.
A deep-dive into the health-economic evidence from the SELECT trial: cost-per-QALY estimates, payer-coverage dynamics, list-price vs net-price reality, and how individual patients can weigh the relative value of semaglutide 2.4 mg for cardiovascular risk reduction.
A deep-dive into the pre-specified and post-hoc subgroup analyses from STEP-8, the first head-to-head RCT of semaglutide 2.4 mg vs liraglutide 3.0 mg, examining which patient profiles drove the largest and smallest weight-loss differences.
Does vaginal estradiol affect appetite or food cravings? An evidence-based look at systemic absorption, central estrogen pathways, and what patients can realistically expect.
A week-by-week guide to vaginal estradiol for genitourinary syndrome of menopause, covering symptom timelines, dosing schedules, side effects, and what the clinical evidence actually shows.
A clinician-level overview of vaginal estradiol formulations, their patent status, generic availability, and what the timeline means for patients treating genitourinary syndrome of menopause. Precise patent dates and prices should be confirmed against current FDA and pharmacy sources before acting.
A clinical review of vaginal estradiol for genitourinary syndrome of menopause in post-bariatric surgery patients, covering the pharmacologic rationale, formulation choices, safety considerations, and where the evidence is extrapolated rather than surgery-specific.
A deep dive into how vardenafil affects sleep architecture, nocturnal erections, PDE5 inhibitor pharmacology during sleep, and what the evidence means for men with erectile dysfunction.
A deep dive into sildenafil's effects on cognition, cerebral blood flow, dementia risk, and brain health. Covers PDE5 inhibition mechanisms, clinical trial data, and practical prescribing considerations.
A guide on how to safely stop sildenafil (Viagra), covering the drug's mechanism, why it does not cause physical dependence, and when to taper or discontinue under medical supervision.
A guide to Humana's Viagra and sildenafil coverage policies, prior authorization criteria, formulary tiers, step therapy requirements, and how to appeal a denial in 2024 to 2025.
A guide to sildenafil (Viagra) storage conditions, shelf-life data, chemical stability research, and what happens when tablets degrade. Includes PubMed-cited evidence and FDA guidance.
A clinician-level review of how sildenafil (Viagra) is metabolized by the liver, what hepatic impairment means for dosing, and which lab changes to monitor.
SELECT trial (n=17,604) found Wegovy cut major cardiovascular events by 20% over 39.8 months, with benefits partly independent of weight loss. NNT ~67.
A citation-dense guide to every clinically significant drug-drug interaction with Wegovy (semaglutide 2.4 mg): mechanisms, affected drug classes, dose-adjustment protocols, and monitoring thresholds.
A guide to semaglutide 2.4 mg (Wegovy) use in patients with autoimmune conditions, covering immune-pathway effects, disease-specific evidence, monitoring protocols, and prescribing considerations.
A clinical review of semaglutide 2.4 mg (Wegovy) and cognitive function, covering trial data, proposed mechanisms, safety signals, and what patients and providers need to know.
A guide to using semaglutide 2.4 mg (Wegovy) after bariatric surgery, covering what is established, what is extrapolated, and what remains unverified in the current evidence base.
Everything patients and clinicians need to know about safely restarting semaglutide 2.4 mg (Wegovy) after an acute illness interruption, including dose re-escalation schedules, monitoring parameters, and evidence-based decision points.
Stopping Wegovy (semaglutide 2.4 mg) typically causes rapid weight regain. Learn exactly how much weight returns, why it happens, and what evidence-based strategies can slow or prevent rebound.
A clinician-level review of how semaglutide 2.4 mg (Wegovy) may affect sexual function in men and women, covering plausible mechanisms, what the pivotal weight-loss trial did and did not measure, and how to think through timing, red flags, and when to seek evaluation.
A comprehensive clinical guide to feminizing hormone therapy for transgender women, covering estrogen and anti-androgen regimens, timelines, monitoring, and how protocols differ by surgical status and age.
Evidence-based guide to testosterone cream dosing for women, including starting doses, titration schedules, lab targets, and how it fits alongside estradiol and progesterone HRT protocols.
HRT can both cause and treat hair loss depending on the hormone type, dose, and individual response. Learn which formulations protect hair, which may thin it, and how to work with your clinician.
Estrogen decline can worsen tinnitus by affecting cochlear blood flow and nerve signaling. See what studies say about HRT easing ear ringing symptoms.
A guide to applying topical hormone therapy products for consistent absorption, even skin coverage, and minimal waste, with dosing evidence, technique breakdowns, and protocol comparisons.
Soy isoflavones, flaxseed lignans, weight management, and less alcohol modestly raise estrogen or ease symptoms; none matches prescription estradiol's potency.
Women's heart attack symptoms often differ sharply from the classic chest-clutching presentation. Learn the 5 most commonly missed warning signs, what the evidence says, and when to call 911.
Menopause changes how your body processes alcohol, making hangovers more intense and longer-lasting. Learn the hormonal science, the risks, and what you can do about it.
Painful sex during menopause is caused by estrogen loss that thins and dries vaginal tissue. Learn the exact mechanisms, proven treatments, and when to call your doctor.
Hot flashes returning, poor sleep, mood swings, or weight gain despite HRT? Learn the clinical signs that your hormone therapy needs adjustment, what causes HRT to stop working, and what your doctor can change to restore relief.
Menopause changes how your body processes alcohol, making hangovers more intense and lasting longer. Learn the hormonal science behind this shift and what you can do about it.
Evidence-based dosing guide for vaginal estradiol (cream, ring, insert, tablet) plus PT-141 and testosterone cream dosing for women.
A comprehensive clinical guide to vaginismus, dyspareunia, HSDD, female orgasmic disorder, and genitourinary syndrome of menopause. Covers diagnosis criteria, FDA-approved treatments, and pelvic floor therapy protocols.
Zepbound slows digestion 30-40%, raising risks with fatty meals, alcohol and herbs like berberine. Learn what to eat, avoid and time around injections.
A analysis of tirzepatide (Zepbound) cancer risk signals, including rodent thyroid findings, post-marketing data, and what current guidelines recommend for screening before and during treatment.
What happens to your weight when you stop Zepbound (tirzepatide)? Learn what SURMOUNT-4 found, how much weight returns, why it happens, and what your clinical options are.
Everything you need to know about traveling with Zepbound (tirzepatide): injection timing, storage across time zones, nausea management in transit, and what to do if you miss a dose mid-trip.
A comprehensive, evidence-based review of zolpidem (Ambien) effects on liver function, including pharmacokinetics, hepatotoxicity risk, dose adjustments for hepatic impairment, and drug interactions affecting liver metabolism.
A deep dive into how zolpidem (Ambien) affects mood, anxiety, depression, memory, and psychiatric risk. Includes trial data, dosing tables, and clinical guidance.
A detailed clinical comparison of Mounjaro (tirzepatide) and Saxenda (liraglutide 3 mg) side-effect profiles, using trial data from SURPASS-2, SCALE, and supporting research to help patients and clinicians choose confidently.
How dulaglutide (Trulicity) works: GLP-1 receptor binding, insulin secretion, glucagon suppression, gastric slowing, and what the REWIND cardiovascular trial does and does not establish.
Leqvio (inclisiran) is a twice-yearly subcutaneous injection cutting LDL-C about 50%. Here's the step-by-step self-injection prep and technique for home use.
Dapagliflozin is metabolized mainly via UGT1A9 glucuronidation, per the FDA label. Covers approved indications, 10 mg dosing, and global regulatory status.
A breakdown of oral semaglutide (Rybelsus) regulatory approvals across the US, EU, Canada, and UK, including approved indications, dosing, mechanism, and what the PIONEER trial program showed.
A clinical deep-dive on how slowing titration, pausing, stepping down, or microdosing AndroGel can reduce secondary testosterone transfer risk to women and children, including real protocols and escalation criteria.
A deep-dive into the clinical implications of the STEP-1 Extension trial: which prescribing patterns shifted, which guidelines updated, and what the weight-regain data means for patients who differ from the trial population.
A deep-dive into the economic modeling, payer-coverage implications, and patient-level value calculations that flow from the STEP-8 head-to-head trial of semaglutide 2.4 mg versus liraglutide 3.0 mg.
A guide to sirolimus pharmacogenomics, dosing, and safety considerations specific to Hispanic and Latino patients, covering CYP3A5 variants, diabetes risk, dyslipidemia, and ethnicity-stratified trial data.
A clinical-grade breakdown of why tirzepatide triggers local subcutaneous histamine release and mechanical tissue responses, with actionable management steps for patients and prescribers.
A clinical deep-dive on how slowing titration, pausing, stepping down, and microdosing AndroGel can resolve gynecomastia caused by excess aromatization. Real protocols, when each works, and when to escalate.
A deep methodological critique of the SELECT trial (semaglutide 2.4 mg, NEJM 2023): enrollment biases, follow-up gaps, statistical caveats, COI concerns, and what post-publication commentary revealed.